Santarus Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Secondary Common Stock Offering

  Santarus Announces Exercise in Full of Option to Purchase Additional Shares
  and Completion of Secondary Common Stock Offering

Business Wire

SAN DIEGO -- May 15, 2013

Santarus, Inc. (NASDAQ: SNTS) today announced the completion of a secondary
underwritten public offering of 4,887,500 shares of its common stock,
including 637,500 shares sold pursuant to the full exercise of an option to
purchase additional shares previously granted to the underwriter. All shares
were offered by Cosmo Technologies Limited at a price to the public of $18.25
per share. Santarus did not sell any shares and will not receive any proceeds
from the offering.

Jefferies LLC acted as the sole book-running manager for the offering.

A shelf registration statement (including a prospectus) relating to these
securities was filed by Santarus with the Securities and Exchange Commission
(SEC) and declared effective by the SEC on April 29, 2009. A final prospectus
supplement and the accompanying prospectus related to the offering have been
filed with the SEC and are available on the SEC’s website located at Copies of the final prospectus supplement and the
accompanying prospectus relating to this offering may also be obtained from
Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 12th floor, New York, NY 10022 or by telephone at 877-547-6340 or by
email at

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other

About Santarus

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring,
developing and commercializing proprietary products that address the needs of
patients treated by physician specialists. The company's current commercial
efforts are focused on five products. UCERIS^™ ^ (budesonide) extended release
tablets for the induction of remission in patients with active, mild to
moderate ulcerative colitis and ZEGERID^® (omeprazole/sodium bicarbonate) for
the treatment of certain upper gastrointestinal disorders are promoted to
gastroenterologists. GLUMETZA^® (metformin hydrochloride extended release
tablets) and CYCLOSET^® (bromocriptine mesylate) tablets, which are indicated
as adjuncts to diet and exercise to improve glycemic control in adults with
type 2 diabetes, and FENOGLIDE^® (fenofibrate) tablets, which is indicated as
an adjunct to diet to reduce high cholesterol, are promoted to
endocrinologists and other physicians who treat patients with type 2 diabetes.
Full prescribing and safety information for Santarus’ products is available at

Santarus’ product development pipeline includes the investigational drug
RUCONEST^® (recombinant human C1 esterase inhibitor). A Biologics License
Application for RUCONEST was submitted to the FDA in April 2013 for the
treatment of acute angioedema attacks in patients with hereditary angioedema.
Santarus is also developing rifamycin SV MMX^®, which is in Phase III clinical
testing for the treatment of travelers’ diarrhea. In addition, the company has
completed a Phase I clinical program with SAN-300, an investigational
monoclonal antibody. More information about Santarus is available at

Santarus cautions you that statements included in this press release that are
not a description of historical facts are forward-looking statements. The
inclusion of forward-looking statements should not be regarded as a
representation by Santarus that any of its plans will be achieved. Actual
results may differ materially from those set forth in this release due to
risks and uncertainties inherent in Santarus’ business, including, without
limitation, difficulties or delays in development, testing, manufacturing and
marketing of, and obtaining and maintaining regulatory approvals for,
Santarus’ products and other risks detailed in Santarus’ prior press releases
as well as in public periodic filings with the SEC, including its Quarterly
Report on Form 10-Q for the quarter ended March 31, 2013.

You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary statement and
Santarus undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as may be
required by applicable law. This caution is made under the safe harbor
provisions of Section 21E of the Private Securities Litigation Reform Act of

Santarus^®, FENOGLIDE^®, UCERIS^™, and ZEGERID^® are trademarks of Santarus,
Inc. GLUMETZA^® is a trademark of Biovail Laboratories International S.r.l.
licensed exclusively in the United States to Depomed, Inc. CYCLOSET^® is a
trademark of VeroScience LLC. MMX^® is a trademark of Cosmo Technologies
Limited. RUCONEST^® is a trademark of Pharming Group N.V.


Martha L. Hough, VP Finance & Investor Relations
(858) 314-5824
Debra P. Crawford, Chief Financial Officer
(858) 314-5708
Westwicke Partners, LLC
Stefan Loren, Ph.D. (
(858) 356-5930
Robert Uhl (
(858) 356-5932
Press spacebar to pause and continue. Press esc to stop.